Sionna Therapeutics

SION

Market cap $2.13B

Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026.

Jennifer Fitzpatrick sold 10,250 shares for a total of approximately $347,000 on March 5, 2026. This transaction represented 100.00% of her direct common stock holdings, reducing direct ownership of common stock to zero.

Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in the fourth quarter. The quarter-end position value rose by $7.43 million, reflecting the purchase of a new position.

OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.